Mass. biotech raises $18M to advance rare-disease drug

07/31/2013 | American City Business Journals

A Series B funding round from new and existing investors has brought in $18 million for Edimer Pharmaceuticals, a Cambridge, Mass.-based biotech firm specializing in treatments for rare genetic conditions. Edimer will use the money to advance clinical development of ED1200, its experimental drug for X-linked hypohidrotic ectodermal dysplasia.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC